吉因加科技，拟港股上市

Core Insights - GeneTech (Shaoxing) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on integrating AI capabilities into the biomarker value chain for precision medicine [1] - The company offers three main solutions: precision diagnostics, drug development empowerment, and clinical research and translation [1] - As of December 14, 2025, GeneTech's solutions have been applied in over 1,000 partner hospitals, with a client base including over 200 biopharmaceutical companies and 500 clinical research institutions [1] Financial Performance - GeneTech's revenue for the years 2022, 2023, 2024, and the first half of 2025 were 1.815 billion, 473 million, 557 million, and 285 million respectively, while net profits were 372 million, 54 million, -424 million, and -414 million [1] - Sales to the top five customers for the years 2022, 2023, 2024, and the first half of 2025 were 583 million, 49 million, 52 million, and 20 million, representing 32.1%, 10.4%, 9.4%, and 6.9% of total revenue [2] - The largest customer sales figures were 168 million, 12 million, 15 million, and 4.5 million, accounting for 9.2%, 2.5%, 2.7%, and 1.6% of total revenue [2] Supplier Relationships - GeneTech's suppliers include laboratory equipment, reagents, consumables, maintenance services, technical equipment and services, property leasing, and human resources services [2] - The total procurement from the top five suppliers accounted for 41.5%, 71.5%, 67.4%, and 68.1% of total procurement for the years 2022, 2023, 2024, and the first half of 2025 [2] - The largest supplier's procurement figures represented 17.1%, 61%, 55.2%, and 58.8% of total procurement [2]